HOLX News and Press, Hologic Inc. From 02/28/22

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – February 24, 2022 – The average American’s lifespan may have increased to 78 years old, but chronic diseases are are still prevalent.  According to the CDC, six in 10 adult...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

While COVID-19 has driven recent quarterly beats, the Street seems to be overlooking the better long-term positioning of Hologic's diagnostics business post-COVID-19. The pandemic greatly accelerated Hologic's diagnostics system placements and the large majority of COVID-19 customers ...

The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February

Image source: The Motley Fool. Hologic (NASDAQ: HOLX) Q1 2022 Earnings Call Feb 02, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Hologic (HOLX) Q1 2022 Earnings Call Transcript

Hologic, Inc. (HOLX) Q1 2022 Earnings Conference Call February 2, 2022 16:30 ET Corporate Participants Ryan Simon - Vice President, Investor Relations Stephen MacMillan - Chairman, President and Chief Executive Officer Karleen Oberton - Chief Financial Officer Conference Call Participants Dan...

Hologic (NASDAQ:HOLX) is trading ~3% higher in the post-market after the healthcare equipment company posted better than expected financials for first quarter of fiscal 2022 and raised the guidance on the strength of COVID-19 testing and base business. Despite the strong revenue bea...

Hologic press release (NASDAQ:HOLX): Q1 Non-GAAP EPS of $2.17 beats by $0.96. Revenue of $1.47B (-8.7% Y/Y) beats by $260M. Shares +5%. Q2 2022 Guidance: Revenue to range between $1.25-$1.3B vs. consensus of $1.06B; GAAP EPS of $1.22-$1.32; Non-GAAP EPS of $1.50-$1.60 vs. consensus of $0.90. ...

– Revenue of $1.471 Billion, GAAP Diluted EPS of $1.95, and Non-GAAP Diluted EPS of $2.17 All Significantly Exceed Expectations – – Broad-Based Organic Revenue Growth of 9% Excluding COVID; Each Division Above 8% Global Growth Excluding COVID – ȁ...